Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.03 HKD | +1.17% | +2.20% | -9.73% |
Apr. 15 | Ocumension Therapeutics Completes Phase III Trials for Postoperative Inflammation Drug | MT |
Apr. 15 | Ocumension Therapeutics Announces Phase III Clinical Trial of OT-502 in China | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-9.73% | 528M | |
+27.92% | 672B | |
+27.03% | 570B | |
-4.59% | 360B | |
+16.38% | 321B | |
+9.39% | 300B | |
+7.44% | 217B | |
+5.35% | 199B | |
-8.47% | 204B | |
-8.58% | 149B |
- Stock Market
- Equities
- 1477 Stock
- News Ocumension Therapeutics
- Ocumension Therapeutics : Wins Regulatory Nod to Start Phase III Trial of Myopia Drug in China